MAS
52
-4
RSG
65
-3
V
64
-2
BMY
55
-8
ISRG
71
-5
KIM
72
2
TSN
50
-2
STI
45
26
BXP
49
-3
GILD
47
-8
AMZN
61
-5
COST
57
-6
AAL
57
-2
DG
8
-2
DTE
43
5
RRC
52
-6
CB
57
2
SYF
86
-6
ROST
57
-3
XYL
35
-2
MAS
52
-4
RSG
65
-3
V
64
-2
BMY
55
-8
ISRG
71
-5
KIM
72
2
TSN
50
-2
STI
45
26
BXP
49
-3
GILD
47
-8
AMZN
61
-5
COST
57
-6
AAL
57
-2
DG
8
-2
DTE
43
5
RRC
52
-6
CB
57
2
SYF
86
-6
ROST
57
-3
XYL
35
-2
Financhill
Back

Autolus Therapeutics PLC 10K Form

Sell
50

AUTL
Autolus Therapeutics PLC

Last Price:
3.08
Seasonality Move:
0.84%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AUTL News And Ratings

See the #1 stock for the next 7 days that we like better than AUTL

AUTL Financial Statistics

Sales & Book Value

Annual Sales: $1.7M
Cash Flow: $-51.92M
Price / Cash Flow: 0
Annual Sales: $1.98
Price / Book: 1.55

Profitability

EPS (TTM): -1.17000
Net Income (TTM): $-233.98M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Autolus Therapeutics PLC Earnings Forecast

Key Autolus Therapeutics PLC Financial Ratios

  • The Research & Development expenses have been 7,684.39% of Revenue.
  • The Interest Expense is -21.63% of Operating Income.
  • The Net Earning history of AUTL is -12,272.26% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 5 years.

Autolus Therapeutics PLC Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AUTL
CUSIP: 05280R
Website: autolus.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AUTL Technical Analysis vs Fundamental Analysis

Sell
50
Autolus Therapeutics PLC (AUTL) is a Sell

Is Autolus Therapeutics PLC a Buy or a Sell?